Timeline – a consumer health biotech company at the forefront of developing innovative solutions for healthy aging and longevity – recently announced that it raised CHF 56 million ($66 million) in an oversubscribed Series D financing round. This marked a significant milestone for the company, including strategic investments from two global industry leaders, L’Oréal and Nestlé.
The funding round was led by BOLD (Business Opportunities for L’Oréal Development), L’Oréal Groupe’s strategic innovation venture capital fund, which underscored investor confidence in the company’s proprietary technology, Mitopure, to help people live healthier for longer.
Mitopure is backed with over 15 years of research and is clinically proven to target a key cellular longevity pathway by recycling and renewing the powerhouses inside cells, the mitochondria. Optimal mitochondrial function is essential for maintaining cellular energy, which supports muscle strength, cognition, immune resilience, skin vitality, and other important benefits, offering a comprehensive approach to promoting healthspan.
The support of these industry leaders and the funds raised will be used to build Timeline into a leading longevity consumer health brand by expanding the science, product categories, and markets across food, beauty, and health sectors.
KEY QUOTES:
“This strategic collaboration reflects the breakthrough multidimensional approach that we’ve always believed is necessary to make meaningful advancements for longevity and healthspan. I want to thank L’Oréal, Nestlé and our longstanding investors for their commitment to longevity solutions rooted in the highest level of science.”
– Patrick Aebischer, Co-Founder and Chairman of Timeline
“Longevity is about living healthier for longer and L’Oréal has been working for a decade to understand and anticipate what this could mean for beauty. Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analyzing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”
– Barbara Lavernos, Deputy Chief Executive Officer and in charge of Research, Innovation and Technology, L’Oréal
“We have been an investor in Timeline since 2019 and continue to be very impressed with the team and stand behind the exponential potential that the Mitopure technology holds for nutrition to help people age better. We’re excited to have L’Oréal join as an investor and strategic partner to bring this technology to new heights and extend its applications.”
– Anna Mohl, CEO of Nestlé Health Science
